121.89
+1.87%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Incyte
From its filings with the US Securities and Exchange Commission
Incyte is based in Wilmington, Delaware and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker INCY. It is a member of the S&P 500. The SEC classifies its business as commercial physical & biological research. In the fiscal year to 31 December 2025, it reported revenue of $5.14bn and net income of $1.29bn. At that date it held total assets of $6.96bn and shareholders' equity of $5.17bn.
Incyte is a global biopharmaceutical company engaged in the discovery, development and commercialization of proprietary therapeutics. Our global headquarters is located in Wilmington, Delaware, where we conduct discovery, clinical development and commercial operations. We also conduct clinical development and commercial operations from our European headquarters in Morges, Switzerland, and our other offices across Europe, as well as our Japanese headquarters in Tokyo and our Canadian headquarters in Montreal.
We are focused in three therapeutic areas that are defined by the indications of our approved medicines and the diseases for which our clinical candidates are being developed. These therapeutic areas are: Hematology, Oncology, and Inflammation and Autoimmunity (“IAI”).
Our hematology franchise includes four approved products, JAKAFI (ruxolitinib), ICLUSIG (ponatinib), MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) and NIKTIMVO (axatilimab-csfr), as well as multiple clinical development programs.
Quoted from its 10-K, filed 10 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 8 Apr 1991
- Employees
- 2,844
- Website
- incyte.com ↗
- Head office
- 1801 AUGUSTINE CUT-OFF, WILMINGTON, DE, 19803
- Incorporated in
- DE
- Classification
- Services-Commercial Physical & Biological Research
- Filer status
- Large accelerated filer
Leadership
Pay as last reported
- Mr. Julian BakerIndependent Chairman of the Board$552,152
- Mr. Bill MeuryPresident, Chief Executive Officer, Director, since 2025
- Mr. Thomas TrayVice President - Finance and Chief Accounting Officer, (Principal Accounting Officer), Principal Financial Officer
- Dr. Pablo CagnoniPresident - Research and Development$7.9m
- Ms. Soni BasiChief Human Resources Officer, Executive Vice President
- Ms. Sheila DentonExecutive Vice President, General Counsel, Corporate Secretary
- Mr. Dave GardnerExecutive Vice President, Chief Strategy Officer
- Mr. Lee HeesonExecutive Vice President - Incyte, International
- Mr. Mohamed IssaExecutive Vice President, Head - US Oncology
- Mr. Michael MorrisseyExecutive Vice President, Head - Global Technical Operations
- Dr. Steven SteinExecutive Vice President, Chief Medical Officer$6.0m
- Mr. Greg ShertzerDirector - Investor Relations
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 80
- Environment
- 80
- Social
- 84
- Governance
- 77
- Direct emissions (scope 1)
- 9,576 t
- Energy emissions (scope 2)
- 6,516 t
- Value chain emissions (scope 3)
- 12,667 t
- Women in the workforce
- 51%
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Incyte Corp holds a strong position in the market with its innovative products, allowing it to capture a significant market share and maintain a competitive edge over its rivals.
- Incyte Corp invests heavily in research and development, resulting in a robust pipeline of novel drugs. This enables the company to introduce new and effective medications, driving growth and improving patient outcomes.
Weaknesses
- Incyte Corp's revenue is heavily reliant on a few key products, which exposes the company to risks such as patent expiry, competition, and regulatory changes. Diversifying the product portfolio could mitigate this vulnerability.
- Compared to larger pharmaceutical companies, Incyte Corp has a relatively smaller market presence. This limits its negotiating power, market reach, and ability to compete on a global scale. Expanding market presence should be a focus for sustained growth.
Opportunities
- The increasing prevalence of cancer and the rising demand for more effective treatments present a significant growth opportunity for Incyte Corp. By leveraging its R&D capabilities, the company can develop innovative therapies to address unmet medical needs.
- Expanding into untapped international markets allows Incyte Corp to access a larger patient population and tap into emerging economies. This can drive revenue growth and decrease dependency on any single market.
Threats
- Incyte Corp operates in a highly competitive industry, where major pharmaceutical companies invest heavily in R&D. Increased competitive pressure can adversely impact market share, pricing, and profitability.
- The pharmaceutical industry is subject to strict regulations and compliance requirements. Non-compliance or changes in regulations can lead to delays in product approvals, increased costs, and potential legal issues for Incyte Corp.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.